CERAMENT® G, BONESUPPORT’s gentamicin-eluting injectable ceramic bone graft substitute, received regulatory approval from Health Canada.
The CE Marked product is presently the subject of FORTIFY, a multicenter 230-patient trial to assess improvement to the standard-of-care management of patients with open fractures of the tibial diaphysis.
Positive data from FORTIFY will be used to support a Premarket Approval filing in the U.S., in anticipation of a 2021 launch.
CERAMENT® G, BONESUPPORT's gentamicin-eluting injectable ceramic bone graft substitute, received regulatory approval from Health Canada.
The CE Marked product is presently the subject of FORTIFY, a multicenter 230-patient trial to assess improvement to the standard-of-care management of patients with open fractures of the...
CERAMENT® G, BONESUPPORT’s gentamicin-eluting injectable ceramic bone graft substitute, received regulatory approval from Health Canada.
The CE Marked product is presently the subject of FORTIFY, a multicenter 230-patient trial to assess improvement to the standard-of-care management of patients with open fractures of the tibial diaphysis.
Positive data from FORTIFY will be used to support a Premarket Approval filing in the U.S., in anticipation of a 2021 launch.
Copy to clipboard 
